Form 4: Amylyx Co-CEO Sells Shares for Tax Obligations

Amylyx Pharmaceuticals' Co-CEO, Justin B. Klee, sold 29,282 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Justin B. Klee, Co-Chief Executive Officer and Director of Amylyx Pharmaceuticals, Inc. (AMLX), reported a transaction involving the company's common stock.
• On March 2, 2026, Mr. Klee disposed of 29,282 shares of common stock.
• The shares were sold at a weighted average price of $14.4717 per share, with individual transaction prices ranging from $14.450 to $15.360.
• The sale was non-discretionary and executed automatically to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Mr. Klee beneficially owns 3,334,616 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. The transaction is a standard, non-discretionary sale for tax purposes, which does not reflect a change in the insider's investment sentiment or the company's operational performance.

Positives

• The sale was explicitly stated as non-discretionary and for tax withholding purposes, which typically mitigates concerns about insider selling based on a negative outlook for the company.

Negatives

• A reduction in an insider's direct shareholding, even for tax purposes, can sometimes be perceived negatively by some investors, though the stated reason clarifies the intent.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that routine tax-related sales by executives are a common occurrence in the pharmaceutical and biotechnology industries, particularly when equity compensation such as restricted stock units vest. These transactions are generally not indicative of a change in management's long-term outlook for the company or its prospects.

Comparison to Industry Standards

• The nature of this transaction, a non-discretionary sale to cover tax obligations upon RSU vesting, is a standard practice across publicly traded companies, including those in the biotechnology sector like Amylyx Pharmaceuticals.
• Comparable companies such as Biogen Inc. (BIIB) or Vertex Pharmaceuticals Incorporated (VRTX) frequently report similar Form 4 filings from their executives for tax-related share dispositions following equity award vesting.

Stakeholder Impact

• Shareholders: Minimal direct impact as the sale is routine and non-discretionary, not signaling a lack of confidence from management.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The reported transaction is a routine, non-discretionary sale by an insider to satisfy tax obligations related to equity compensation. It does not indicate a change in the company's fundamentals or the insider's long-term view of the company's prospects. Therefore, it provides no new information that would warrant a change in investment strategy, suggesting a 'hold' recommendation.

Keywords

Amylyx Pharmaceuticals, AMLX, Justin Klee, Insider Trading, Stock Sale, Tax Withholding, Restricted Stock Units, RSU, Form 4